{"schema_version":"secwatch.filing_event.v1","accession":"0001804220-23-000005","form_type":"8-K","ticker":"REGN","cik":"0000872589","company_name":"REGENERON PHARMACEUTICALS, INC.","filed_at":"2023-02-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.329624+00:00","generated_at":"2026-06-20T01:31:18.056040+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Regeneron Q4 revenue down 31% to $3.41B, core up 14%; GAAP EPS $10.50","bullets":["Q4 total revenues $3.41B (-31% YoY); ex-REGEN-COV/Ronapreve up 14% to $3.02B.","GAAP diluted EPS $10.50 (Q4) and $38.22 (FY); non-GAAP $12.56 (Q4) and $44.98 (FY).","EYLEA U.S. net sales $1.50B Q4 (-3%), FY $6.26B (+8%); Dupixent global net sales $2.45B Q4 (+38%), FY $8.68B (+40%).","Aflibercept 8 mg BLA submitted for wet AMD/DME in Dec 2022; FDA approved Libtayo+chemo for NSCLC; EC approved Dupixent for prurigo nodularis and EoE.","New $3.0B share repurchase program authorized Jan 2023; FY2023 guidance: non-GAAP R&D $3.725-3.925B, non-GAAP SG&A $2.130-2.280B."],"urls":{"canonical":"https://secwatch.observer/filing/0001804220-23-000005","json":"https://secwatch.observer/filing/0001804220-23-000005.json","markdown":"https://secwatch.observer/filing/0001804220-23-000005.md","text":"https://secwatch.observer/filing/0001804220-23-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872589/000180422023000005/0001804220-23-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872589/000180422023000005/regn-20230203.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T01:31:18.056040+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b6f9dd98eb70bd88d99fd5cad5482af5f93ee5a3","claim":"REGENERON PHARMACEUTICALS, INC. reported Fourth Quarter 2022 results: revenue $3,414 million, net income $1,197 million, EPS $10.50.","evidence_excerpt":"99.1 Document Exhibit 99.1 Press Release Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results • Fourth quarter 2022 revenues decreased 31% to $3.41 billion versus fourth quarter 2021; excluding REGEN-COV ® and Ronapreve TM (a)(b) , revenues increased 14% • Full year 2022 revenues decreased 24% to $12.17 billion versus full year","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/872589/000180422023000005/0001804220-23-000005-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Fourth Quarter 2022"},{"label":"Revenue","value":"$3,414 million"},{"label":"Net income","value":"$1,197 million"},{"label":"EPS","value":"$10.50"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}